Facit-backed oncological development initiative Triphase Accelerator has struck a deal with Celgene for its TRPH-395 blood cancer treatment as the drug nears clinical trials
Triphase Accelerator, a Canada-based oncological treatment accelerator backed by commercialisation agency Fight Against Cancer Innovation Trust (Facit), is to receive $40m upfront under a business development pact with drug maker Celgene. Facit provides funding to advance local oncological projects including spinouts and is allied to the Ontario Institute for Cancer Research. Under the partnership, Triphase…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
